Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Blood first assay screening in treatment-naïve NSCLC: initial results from the ALK+ cohort

Shirish Gadgeel, University of Michigan, Ann Arbor, MI, gives an update on the ALK+ cohort of the Blood First Assay Screening Trial (BFAST) in patients (pts) with treatment-naïve non-small cell lung cancer (NSCLC), comparing the results to the previous ALEX study (NCT02075840). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.